Fernando Aguirre
Known title: DirectorCIK: 0001224983
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status. CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.
Transaction History
| SYF | ▲ Buy | Grant | 846 | $60K | 9/30/2026 | View on chart |
| SYF | ▲ Buy | Grant | 14 | $1K | 8/17/2026 | View on chart |
| SYF | ▲ Buy | Grant | 789 | $60K | 6/30/2026 | View on chart |
| CVS | ▼ Sell | Other | 1,563 | $146K | 5/21/2026 | View on chart |
| CVS | ▼ Sell | Other | 30,437 | $2.9M | 5/20/2026 | View on chart |
| SYF | ▲ Buy | Grant | 14 | $999 | 5/15/2026 | View on chart |
| CVS | ▲ Buy | Grant | 1,563 | $152K | 5/14/2026 | View on chart |
| SYF | ▲ Buy | Grant | 883 | $60K | 3/31/2026 | View on chart |
| SYF | ▲ Buy | Grant | 14 | $1K | 2/17/2026 | View on chart |
| SYF | ▲ Buy | Grant | 660 | $55K | 12/31/2025 | View on chart |
| CVS | ▲ Buy | Grant | 1,800 | $137K | 11/20/2025 | View on chart |
| SYF | ▲ Buy | Grant | 15 | $1K | 11/17/2025 | View on chart |
| SYF | ▲ Buy | Grant | 775 | $55K | 9/30/2025 | View on chart |
| SYF | ▲ Buy | Grant | 15 | $1K | 8/15/2025 | View on chart |
| SYF | ▲ Buy | Grant | 825 | $55K | 6/30/2025 | View on chart |
| CVS | ▲ Buy | Grant | 2,263 | $137K | 5/15/2025 | View on chart |
| SYF | ▲ Buy | Grant | 17 | $1K | 5/15/2025 | View on chart |
| SYF | ▲ Buy | Grant | 1,039 | $55K | 3/31/2025 | View on chart |
| SYF | ▲ Buy | Grant | 13 | $849 | 2/18/2025 | View on chart |
| SYF | ▲ Buy | Grant | 635 | $41K | 12/31/2024 | View on chart |
| CVS | ▲ Buy | Grant | 2,364 | $135K | 11/21/2024 | View on chart |
| SYF | ▲ Buy | Grant | 15 | $975 | 11/15/2024 | View on chart |
| SYF | ▲ Buy | Grant | 827 | $41K | 9/30/2024 | View on chart |
| SYF | ▲ Buy | Grant | 23 | $1K | 8/15/2024 | View on chart |
| SYF | ▲ Buy | Grant | 875 | $41K | 6/30/2024 | View on chart |
| CVS | ▲ Buy | Grant | 2,347 | $135K | 5/16/2024 | View on chart |
| SYF | ▲ Buy | Grant | 26 | $1K | 5/15/2024 | View on chart |
| SYF | ▲ Buy | Grant | 957 | $41K | 3/31/2024 | View on chart |
| SYF | ▲ Buy | Grant | 33 | $1K | 2/15/2024 | View on chart |
| SYF | ▲ Buy | Grant | 1,081 | $41K | 12/31/2023 | View on chart |
| CVS | ▲ Buy | Grant | 1,998 | $138K | 11/15/2023 | View on chart |
| SYF | ▲ Buy | Grant | 45 | $1K | 11/9/2023 | View on chart |
| SYF | ▲ Buy | Grant | 1,350 | $41K | 9/30/2023 | View on chart |
| SYF | ▲ Buy | Grant | 39 | $1K | 8/10/2023 | View on chart |
| SYF | ▲ Buy | Grant | 1,217 | $41K | 6/30/2023 | View on chart |
| CVS | ▲ Buy | Grant | 1,329 | $92K | 5/18/2023 | View on chart |
| SYF | ▲ Buy | Grant | 48 | $1K | 5/12/2023 | View on chart |
| SYF | ▲ Buy | Grant | 1,419 | $41K | 3/31/2023 | View on chart |
| SYF | ▲ Buy | Grant | 35 | $1K | 2/17/2023 | View on chart |
| SYF | ▲ Buy | Grant | 1,256 | $41K | 12/31/2022 | View on chart |
| CVS | ▲ Buy | Grant | 1,323 | $126K | 11/17/2022 | View on chart |
| SYF | ▲ Buy | Grant | 30 | $1K | 11/10/2022 | View on chart |
| SYF | ▲ Buy | Grant | 1,464 | $41K | 9/30/2022 | View on chart |
| SYF | ▲ Buy | Grant | 28 | $1K | 8/11/2022 | View on chart |
| SYF | ▲ Buy | Grant | 1,494 | $41K | 6/30/2022 | View on chart |
| SYF | ▲ Buy | Grant | 24 | $793 | 5/12/2022 | View on chart |
| CVS | ▲ Buy | Grant | 1,282 | $126K | 5/11/2022 | View on chart |
| SYF | ▲ Buy | Grant | 1,186 | $41K | 3/31/2022 | View on chart |
| SYF | ▲ Buy | Grant | 17 | $742 | 2/17/2022 | View on chart |
| SYF | ▲ Buy | Grant | 890 | $41K | 12/31/2021 | View on chart |
| CVS | ▲ Buy | Grant | 1,253 | $116K | 11/17/2021 | View on chart |
| SYF | ▲ Buy | Grant | 15 | $753 | 11/12/2021 | View on chart |
| SYF | ▲ Buy | Grant | 844 | $41K | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Synchrony Financial Prepares for Q3 Earnings Amid Mixed Analyst Views
Synchrony Financial is approaching its third-quarter earnings report, with analysts expecting lower results compared to previous periods. While some market participants are watching for higher purchase volumes to support performance, recent stock price movements have been volatile. The company's current valuation remains low relative to its peer group, and its preferred shares have seen increased interest due to yield.
Synchrony Financial Prepares for Q3 Earnings Amid Mixed Analyst Views. Synchrony Financial is approaching its third-quarter earnings report, with analysts expecting lower results compared to previous periods. While some market participants are watching for higher purchase volumes to support performance, recent stock price movements have been volatile. The company's current valuation remains low relative to its peer group, and its preferred shares have seen increased interest due to yield.